We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

186 hedge funds and large institutions have $466M invested in PDL BioPharma, Inc. in 2017 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 63 increasing their positions, 44 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 13

45% more capital invested

Capital invested by funds: $321M → $466M (+$145M)

43% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 44

9% more funds holding

Funds holding: 171 → 186 (+15)

37% less call options, than puts

Call options by funds: $450K | Put options by funds: $717K

Holders
186
Holders Change
+15
Holders Change %
+8.77%
% of All Funds
4.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
63
Reduced
44
Closed
13
Calls
$450K
Puts
$717K
Net Calls
-$267K
Net Calls Change
-$555K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$8.55M
2
Morgan Stanley
Morgan Stanley
New York
+$6.49M
3
State Street
State Street
Massachusetts
+$5.81M
4
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
+$3.96M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.56M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$9.56M
2
Bank of America
Bank of America
North Carolina
-$4.6M
3
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
-$3.61M
4
BlackRock
BlackRock
New York
-$2.18M
5
Deutsche Bank
Deutsche Bank
Germany
-$2M
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
176
IFP Advisors
Florida
$2K – – –
LWCFA
177
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$2K – – –
DA
178
Denali Advisors
California
$1K – – –
GT
179
Glenmede Trust
Pennsylvania
$1K – – –
WA
180
Winfield Associates
Ohio
$1K – – –
Northwestern Mutual Wealth Management
181
Northwestern Mutual Wealth Management
Wisconsin
$1K +$484 +174 New
Walleye Trading
182
Walleye Trading
New York
$431 +$353K +127,000 New
TC
183
TFS Capital
Pennsylvania
– -$824K -333,728 Closed
Schroder Investment Management Group
184
Schroder Investment Management Group
United Kingdom
– -$783K -303,534 Closed
First Trust Advisors
185
First Trust Advisors
Illinois
– -$317K -128,338 Closed
LSV Asset Management
186
LSV Asset Management
Illinois
– -$190K -77,100 Closed
ARTA
187
A.R.T. Advisors
New York
– -$96K -39,109 Closed
SSW
188
Smith Shellnut Wilson
Mississippi
– -$85K -27,196 Closed
TSS
189
Two Sigma Securities
New York
– -$40K -16,325 Closed
HF
190
HRT Financial
New York
– -$35K -14,205 Closed
AIM
191
Acrospire Investment Management
Illinois
– -$24K -9,898 Closed
PAM
192
Panagora Asset Management
Massachusetts
– -$11K -4,366 Closed
WCBA
193
Weaver C. Barksdale & Associates
Tennessee
– -$2K -739 Closed
IWM
194
IHT Wealth Management
Illinois
– -$333 -425 Closed
US Bancorp
195
US Bancorp
Minnesota
– -$1K -300 Closed
SPIA
196
Steward Partners Investment Advisory
New York
– -$651 -234 -50%
AssetMark Inc
197
AssetMark Inc
California
– +$392 +141 +3,525%
4 5 6 7
8

PDLI Hedge Fund Activity: Q3 2017 in Review

186 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2017, worth a combined $466M — up 45% from $321M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new PDLI positions and 13 closed out — a net gain of 18 holders — while 63 added to existing stakes and 44 trimmed.

The largest buyer was Millennium Management, adding an estimated $8.55M. The largest seller was Citadel Advisors, cutting an estimated $9.56M.

  • 186 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2017, up from 171 in Q2 2017.
  • Funds reported $466M of PDL BioPharma, Inc. stock for Q3 2017, up 45% quarter-over-quarter.
  • 31 funds opened new PDL BioPharma, Inc. positions in Q3 2017 and 13 closed out, a net change of +18 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2017 was Millennium Management, an estimated $8.55M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2017 was Citadel Advisors, an estimated $9.56M sold.

Based on aggregated 13F filings for Q3 2017.